<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9.     Summary of Mean (±Standard Deviation) Irinotecan and SN-38 Pharmacokinetic Parameters in Patients with Solid Tumors</caption>
<col align="center" valign="top" width="20"></col>
<col align="center" valign="top" width="10"></col>
<col align="center" valign="top" width="10"></col>
<col align="center" valign="top" width="10"></col>
<col align="center" valign="top" width="10"></col>
<col align="center" valign="top" width="10"></col>
<col align="center" valign="top" width="10"></col>
<col align="center" valign="top" width="10"></col>
<col align="center" valign="top" width="10"></col>
<thead>
<tr>
<th rowspan="2" stylecode="Rrule Botrule" valign="middle">Dose<br/>(mg/m<sup>2</sup>)</th>
<th colspan="5" stylecode="Rrule Botrule">Irinotecan</th>
<th colspan="3" stylecode="Botrule">SN-38</th>
</tr>
<tr>
<th stylecode="Rrule">C<sub>max</sub>
<br/>(ng/mL)</th>
<th stylecode="Rrule">AUC<sub>0–24</sub>
<br/>(ng∙h/mL)</th>
<th stylecode="Rrule">t<sub>1/2</sub>
<br/>(h)</th>
<th stylecode="Rrule">V<sub>z</sub>
<br/>(L/m<sup>2</sup>)</th>
<th stylecode="Rrule">CL<br/>(L/h/m<sup>2</sup>)</th>
<th stylecode="Rrule">C<sub>max</sub>
<br/>(ng/mL)</th>
<th stylecode="Rrule">AUC<sub>0–24</sub>
<br/>(ng∙h/mL)</th>
<th>t<sub>1/2</sub>
<br/>(h)</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="9">C<sub>max </sub>- Maximum plasma concentration</td>
</tr>
<tr>
<td align="left" colspan="9">AUC<sub>0–24 </sub>- Area under the plasma concentration-time curve from time</td>
</tr>
<tr>
<td align="left" colspan="9">0 to 24 hours after the end of the 90-minute infusion</td>
</tr>
<tr>
<td align="left" colspan="9">t<sub>1/2 </sub>- Terminal elimination half-life</td>
</tr>
<tr>
<td align="left" colspan="9">V<sub>z</sub> - Volume of distribution of terminal elimination phase</td>
</tr>
<tr>
<td align="left" colspan="9">CL - Total systemic clearance</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Rrule">125<br/>(N=64)</td>
<td stylecode="Rrule">1,660 <br/>±797</td>
<td stylecode="Rrule">10,200<br/> ±3,270</td>
<td stylecode="Rrule">5.8<footnote id="t9f1">Plasma specimens collected for 24 hours following the end of the 90-minute infusion.</footnote>
<br/>±0.7</td>
<td stylecode="Rrule">110<br/>±48.5</td>
<td stylecode="Rrule">13.3<br/>±6.01</td>
<td stylecode="Rrule">26.3<br/>±11.9</td>
<td stylecode="Rrule">229<br/>±108</td>
<td>10.4<footnoteref idref="t9f1"></footnoteref>
<br/>±3.1</td>
</tr>
<tr>
<td stylecode="Rrule">340<br/>(N=6)</td>
<td stylecode="Rrule">3,392<br/>±874</td>
<td stylecode="Rrule">20,604<br/>±6,027</td>
<td stylecode="Rrule">11.7<footnote id="t9f2">Plasma specimens collected for 48 hours following the end of the 90-minute infusion. Because of the longer collection period, these values provide a more accurate reflection of the terminal elimination half-lives of irinotecan and SN-38.</footnote>
<br/>±1.0</td>
<td stylecode="Rrule">234<br/>±69.6</td>
<td stylecode="Rrule">13.9<br/>±4.0</td>
<td stylecode="Rrule">56.0<br/>±28.2</td>
<td stylecode="Rrule">474<br/>±245</td>
<td>21.0<footnoteref idref="t9f2"></footnoteref>
<br/>±4.3</td>
</tr>
</tbody>
</table>